A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study).

Trial Profile

A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.
    • 07 Jun 2016 Results analyzing Quality of life (QOL) outcome with letrozole treatment presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Interim results of 5 years presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top